VACH
NASDAQVoyager Acquisition Corp
IPO2024
$11.53+0.10 (+0.83%)
News25/Ratings0
Price$11.53+0.94 (+8.83%)
2026-01-202026-04-23
News · 26 weeks17-71%
2025-10-262026-04-19
Mix1690d
- SEC Filings9(56%)
- Other4(25%)
- Offering3(19%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Voyager Acquisition CorpSCHEDULE 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- SECAmendment: SEC Form 10-K/A filed by Voyager Acquisition Corp10-K/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)
- SECSEC Form 425 filed by Voyager Acquisition Corp425 - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- SECVoyager Acquisition Corp filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)
- PRVoyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AGBROOKLYN, N.Y., March 13, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: "VACHU," "VACH," "VACHW") ("Voyager" or the "Company") held the general meeting on March 12, 2026 and approved the previously announced business combination (the "Business Combination") with VERAXA Biotech AG ("VERAXA"). After the closing of the Business Combination, it is expected that the combined company will trade on Nasdaq under the new symbol ("VRXA"). As previously announced, holders of 25,217,315 of the Company's Class A ordinary shares ("Class A shares") exercised their right to redeem their shares for a pro rata portion of the funds in the Company's trust account, reflecting redemptions of
- SECSEC Form 425 filed by Voyager Acquisition Corp425 - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- PRVoyager Acquisition Corporation Announces Redemption Results in Connection with its Business Combination with VERAXA Biotech AGBROOKLYN, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: "VACHU," "VACH," "VACHW") ("Voyager" or the "Company") today announced that holders of 25,217,315 of the Company's Class A ordinary shares ("Class A shares") exercised their right to redeem their shares for a pro rata portion of the funds in the Company's trust account, reflecting redemptions of approximately 99.67% of the total Class A shares outstanding in connection with the completion of the Company's business combination (the "Business Combination") pursuant to the business combination agreement between the Company, VERAXA Biotech AG ("VERAXA") and the other parties thereto (the "Business Combi
- SECSEC Form 10-K filed by Voyager Acquisition Corp10-K - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)
- PRVERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.ZURICH, SWITZERLAND – March 2, 2026 -- VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies, today announced that its shareholders approved the merger between VERAXA and Veraxa Biotech Holding AG and the issuance of new shares of the combined company at the Extraordinary General Meeting ("EGM") on February 27, 2026. Both resolutions are prerequisites for the closing of the proposed business combination (the "Business Combination") among VERAXA, Veraxa Biotech Holding AG and Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager"), "Voyager"), a special purpose acquisition company sponsored by Cantor Fitzgerald & Co., Voyager Acquisition Sponsor Holdco LLC, and Odeon
- SECVoyager Acquisition Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)
- SECSEC Form 425 filed by Voyager Acquisition Corp425 - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Voyager Acquisition CorpSCHEDULE 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Voyager Acquisition CorpSCHEDULE 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- SECSEC Form SCHEDULE 13G filed by Voyager Acquisition CorpSCHEDULE 13G - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- SECSEC Form 425 filed by Voyager Acquisition Corp425 - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- SECVoyager Acquisition Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)
- SECSEC Form 10-Q filed by Voyager Acquisition Corp10-Q - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)
- SECVoyager Acquisition Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)
- SECSEC Form 425 filed by Voyager Acquisition Corp425 - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- PRVERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in ImmunologyZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY – September 30, 2025 -- VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager")), and Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, today announced a strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs). The combination of both technology platforms aims to unlock novel targeted therapies for the treatment of autoimmune and chronic immune diseases AOCs combine the specificity of monoclonal anti
- SECSEC Form 425 filed by Voyager Acquisition Corp425 - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- SECVoyager Acquisition Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)
- SECSEC Form 10-Q filed by Voyager Acquisition Corp10-Q - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Voyager Acquisition CorpSCHEDULE 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Voyager Acquisition CorpSCHEDULE 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)